At this time, there does seem to be a growing body of basic pharmacologic data suggesting there may be a role for CBD, especially in the treatment of refractory epilepsy. However, given the lack of well-controlled trials, we must also ask if we are getting ahead of ourselves. Clearly, this is an emotionally and politically charged issue. If this were any other uninvestigated pharmaceutical compound, would we feel as compelled to make the agent widely available before statistically valid class 1 evidence was available for review? Until data from well-designed clinical trials are available and reliable, and standardized CBD products that are produced using GMP are available, caution must be exercised in any consideration of using CBD for the treatment of epilepsy. In the meantime, based upon promising preliminary data, further clinical research should be wholeheartedly pursued.
Rather, what most of these oils appear to be are extracts of the hemp seed. As we mentioned earlier, CBD oil can be made from either hemp or marijuana cannabis plants. No matter which plant they come from, however, they must be made using the flowers, leaves, stem and stalks of the plant, as these are the parts where the CBD compound is actually located.